205 related articles for article (PubMed ID: 38163846)
1. Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.
Wang Y; Zhang P; Chao Y; Zhu Z; Yang C; Zhou Z; Li Y; Long Y; Liu Y; Li D; Wang S; Qu Q
Cell Res; 2024 Jan; 34(1):47-57. PubMed ID: 38163846
[TBL] [Abstract][Full Text] [Related]
2. Transport and inhibition mechanisms of human VMAT2.
Wu D; Chen Q; Yu Z; Huang B; Zhao J; Wang Y; Su J; Zhou F; Yan R; Li N; Zhao Y; Jiang D
Nature; 2024 Feb; 626(7998):427-434. PubMed ID: 38081299
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
[TBL] [Abstract][Full Text] [Related]
4. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.
Yaffe D; Vergara-Jaque A; Forrest LR; Schuldiner S
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):E7390-E7398. PubMed ID: 27821772
[TBL] [Abstract][Full Text] [Related]
5. Structural mechanisms for VMAT2 inhibition by tetrabenazine.
Dalton MP; Cheng MH; Bahar I; Coleman JA
Elife; 2024 Mar; 12():. PubMed ID: 38517752
[TBL] [Abstract][Full Text] [Related]
6. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine.
Peter D; Vu T; Edwards RH
J Biol Chem; 1996 Feb; 271(6):2979-86. PubMed ID: 8621690
[TBL] [Abstract][Full Text] [Related]
7. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
Bernstein AI; Stout KA; Miller GW
J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
[TBL] [Abstract][Full Text] [Related]
8. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
9. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
Koch J; Shi WX; Dashtipour K
Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
[TBL] [Abstract][Full Text] [Related]
10. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
Finn JP; Edwards RH
J Biol Chem; 1997 Jun; 272(26):16301-7. PubMed ID: 9195934
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone.
Støve SI; Skjevik ÅA; Teigen K; Martinez A
Commun Biol; 2022 Nov; 5(1):1283. PubMed ID: 36418492
[TBL] [Abstract][Full Text] [Related]
12. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
13. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanisms for VMAT2 inhibition by tetrabenazine.
Dalton MP; Cheng MH; Bahar I; Coleman JA
bioRxiv; 2024 Feb; ():. PubMed ID: 37732203
[TBL] [Abstract][Full Text] [Related]
15. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
Gopalakrishnan A; Sievert M; Ruoho AE
Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
[TBL] [Abstract][Full Text] [Related]
16. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
Yang Y; Yu D; Zhu X; Du G; Wang W; Zou F; Wang H; Zhang R; Ye L; Tian J
Eur J Med Chem; 2021 Nov; 224():113718. PubMed ID: 34329999
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Yasumoto S; Tamura K; Karasawa J; Hasegawa R; Ikeda K; Yamamoto T; Yamamoto H
Neurosci Lett; 2009 May; 454(3):229-32. PubMed ID: 19429089
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.
Stahl SM
CNS Spectr; 2018 Feb; 23(1):1-6. PubMed ID: 29249207
[TBL] [Abstract][Full Text] [Related]
20. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
